{'52WeekChange': 0.16917849,
 'SandP52WeekChange': None,
 'address1': '225 Binney Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 273.34,
 'askSize': 800,
 'averageDailyVolume10Day': 977087,
 'averageVolume': 1584706,
 'averageVolume10days': 977087,
 'beta': 0.513165,
 'beta3Year': None,
 'bid': 272.41,
 'bidSize': 800,
 'bookValue': 71.438,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 277.26,
 'dayLow': 270.68,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': 0.032,
 'enterpriseToEbitda': 11.151,
 'enterpriseToRevenue': 6.193,
 'enterpriseValue': 89718513664,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 276.59314,
 'fiftyTwoWeekHigh': 374.99,
 'fiftyTwoWeekLow': 215.78,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 314660689,
 'forwardEps': 31.76,
 'forwardPE': 8.574622,
 'fromCurrency': None,
 'fullTimeEmployees': 7400,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.00657,
 'heldPercentInstitutions': 0.93154997,
 'industry': 'Drug Manufacturers—General',
 'isEsgPopulated': True,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 979776000,
 'lastSplitFactor': '3:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/biogen.com',
 'longBusinessSummary': 'Biogen Inc. discovers, develops, manufactures, and '
                        'delivers therapies for treating neurological and '
                        'neurodegenerative diseases worldwide. The company '
                        'offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and '
                        'FAMPYRA for multiple sclerosis (MS); SPINRAZA for the '
                        'treatment of spinal muscular atrophy; and FUMADERM to '
                        'treat plaque psoriasis. It also provides BENEPALI, an '
                        'etanercept biosimilar referencing ENBREL; IMRALDI, an '
                        'adalimumab biosimilar referencing HUMIRA; and '
                        'FLIXABI, an infliximab biosimilar referencing '
                        'REMICADE. In addition, the company offers RITUXAN for '
                        "the treatment of non-Hodgkin's lymphoma, chronic "
                        'lymphocytic leukemia (CLL), rheumatoid arthritis, two '
                        'forms of ANCA-associated vasculitis, and pemphigus '
                        "vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma "
                        'and CLL; GAZYVA to treat CLL and follicular lymphoma; '
                        'and OCREVUS for the treatment of relapsing MS and '
                        'primary progressive MS; and other anti-CD20 '
                        'therapies. Further, it is involved in developing '
                        'Opicinumab, BIIB061, and BIIB091 for MS and '
                        'neuroimmunology; Aducanumab, BAN2401, BIIB092, '
                        "BIIB076, and BIIB080 to treat Alzheimer's disease and "
                        'dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to '
                        'treat neuromuscular disorders; BIIB054 and BIIB094 '
                        'for treating movement disorders; BIIB111 and BIIB112 '
                        'for ophthalmology; Dapirolizumab pegol and BIIB059 to '
                        'treat immunology and others; BIIB104 for '
                        'neurocognitive disorders; BIIB093, TMS-007, and '
                        'Natalizumab to treat acute neurology; BIIB074 and '
                        'BIIB095 for pain; and SB11 biosimilar, which are '
                        'under various stages of development. The company '
                        'offers products through its sales force and marketing '
                        'groups. Biogen Inc. has collaboration agreements with '
                        'Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai '
                        'Co., Ltd.; Alkermes Pharma Ireland Limited; '
                        'Bristol-Myers Squibb Company; Acorda Therapeutics, '
                        'Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; '
                        'Neurimmune SubOne AG; and Sangamo Therapeutics Inc. '
                        'The company was founded in 1978 and is headquartered '
                        'in Cambridge, Massachusetts.',
 'longName': 'Biogen Inc.',
 'market': 'us_market',
 'marketCap': 43113373696,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_29726',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1593475200,
 'navPrice': None,
 'netIncomeToCommon': 5926799872,
 'nextFiscalYearEnd': 1640908800,
 'open': 277.26,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -3.56,
 'phone': '617 679 2000',
 'previousClose': 278.51,
 'priceHint': 2,
 'priceToBook': 3.8121164,
 'priceToSalesTrailing12Months': 2.9759426,
 'profitMargins': 0.4091,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 277.26,
 'regularMarketDayLow': 270.68,
 'regularMarketOpen': 277.26,
 'regularMarketPreviousClose': 278.51,
 'regularMarketPrice': 277.26,
 'regularMarketVolume': 862283,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 158312992,
 'sharesPercentSharesOut': 0.02,
 'sharesShort': 3261515,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4534532,
 'shortName': 'Biogen Inc.',
 'shortPercentOfFloat': 0.0201,
 'shortRatio': 1.58,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'BIIB',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 34.044,
 'trailingPE': 7.999354,
 'twoHundredDayAverage': 299.13647,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '9f757b3b-bb17-33fd-9f97-b619c9193382',
 'volume': 862283,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.biogen.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02142'}